Every 8-K that HARVARD APPRATS REG TCH (HRGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow HRGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRGN filings page.
Harvard Apparatus Regenerative Technology, Inc. entered into two short-term bridge loan arrangements with its Chairman and Chief Executive Officer, Junli He, providing a total of $400,000 in funding. A $200,000 Bridge Note dated May 8, 2026 and a second $200,000 Bridge Note dated July 16, 2026 each bear a fixed annual interest rate of 8%, calculated on a 360-day year.
For each note, all principal and accrued interest are due on the earlier of the company's next capital raise with at least $5,000,000 in gross proceeds or the one-year anniversary of the note's date. If the company completes an equity financing of at least $200,000 before maturity, the lender may elect to convert the outstanding balance into the new securities at the financing price. The notes are prepayable at any time without penalty, include customary covenants and events of default, and were approved as related party transactions by the disinterested directors. Aggregate principal outstanding under the Bridge Notes is $400,000.
Harvard Apparatus Regenerative Technology, Inc. entered into a loan arrangement on April 13, 2026, under which Chairman and Chief Executive Officer Junli He agreed to provide the company with a $300,000 Bridge Note. The note carries a fixed annual interest rate of 8% and includes covenants and customary events of default.
The principal and accrued interest become due on the earlier of the company’s next capital raise with at least $5,000,000 in gross proceeds or April 13, 2027. The Bridge Note allows optional conversion at the lender’s discretion. This report also corrects a prior classification error, re-reporting the loan as an Item 1.01 entry into a material definitive agreement rather than a termination under Item 1.02.
Harvard Apparatus Regenerative Technology, Inc. held its Annual Meeting of Stockholders on June 18, 2026. Stockholders elected three Class I Directors — Junli (Jerry) He, James Shmerling, and Mao Zhang — each for a one-year term ending at the 2027 annual meeting.
Shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 14,077,329 votes for. They also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 12,467,264 votes for.
Harvard Apparatus Regenerative Technology, Inc. filed an 8-K to share that the first patient has been treated with its Cellspan™ Esophageal Implant (CEI) in a Phase 1 feasibility and safety clinical trial at the Mayo Clinic in Rochester, Minnesota.
The CEI is a combination product using a modified polyurethane CellFrame™ mesh scaffold seeded with a patient’s own adipose-derived Mesenchymal Stromal Cells, temporarily supporting tissue growth before scaffold removal 21–42 days after implantation. The company highlights this as a key milestone in its effort to offer a regenerative option for life‑threatening esophageal disease, which currently relies on highly invasive procedures.
Harvard Apparatus Regenerative Technology, Inc. entered into a related-party bridge loan with its Chairman and CEO, Junli He, for $300,000, documented in a Bridge Note bearing a fixed 8% annual interest rate.
The principal and accrued interest are due on the earlier of the company’s next capital raise with at least $5,000,000 in gross proceeds or April 13, 2027. The Bridge Note includes optional conversion at the lender’s discretion, covenants, and customary events of default such as failure to pay amounts due or comply with its terms.
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors for a private placement of its common stock. The investors agreed to buy an aggregate of 411,765 shares of common stock at a purchase price of $1.70 per share, for an aggregate purchase price of approximately $0.7 million.
The shares were sold in a private transaction relying on exemptions from Securities Act registration, including Section 4(a)(2) for transactions not involving a public offering and Rule 506 for sales to an accredited investor, as well as similar state law exemptions. The Purchase Agreements contain customary representations, warranties, and covenants, and a form of the agreement is filed as an exhibit to the report.